For research and educational purposes only. Not intended for human consumption.
Ipamorelin
Well Researched- •Phase II postoperative ileus trials completed
- •Bone growth and muscle preservation data
- •CJC-1295 synergy research updated
Growth Hormone Secretagogue | Selective GHRP
Overview
What is Ipamorelin?
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates natural growth hormone production from the pituitary gland. Known for its clean profile with minimal side effects on cortisol and prolactin levels, making it ideal for body composition, recovery, and anti-aging applications. Phase II clinical trials confirm safety and tolerability in healthy adults, with ongoing research into synergistic combinations with CJC-1295 for enhanced GH optimization. Banned by WADA
Key Benefits
Optimal growth hormone stimulation with precise dosing and superior bioavailability. Most effective method for body composition, recovery, and anti-aging applications with minimal side effects. Preclinical data shows bone growth promotion and muscle preservation against steroid-induced breakdown.
Mechanism of Action
Injectable Ipamorelin mimics ghrelin to stimulate pituitary GH release selectively without affecting cortisol, prolactin, or causing significant hunger. Research shows enhanced tetanic tension and muscle preservation in glucocorticoid-damaged models when combined with CJC-1295.
Molecular Information
Pharmacokinetics
Research Indications
Natural GH Stimulation
Stimulates pituitary gland to release growth hormone naturally with consistent elevation 30-60 minutes post-injection.
IGF-1 Enhancement
Increases insulin-like growth factor-1 production through natural GH pathways.
Anti-Aging Benefits
Supports cellular regeneration, collagen synthesis, and metabolic function through enhanced growth hormone pathways.
Research Protocols
Disclaimer: Ipamorelin has a saturation dose (~100mcg) beyond which additional GH release diminishes. Split dosing 2-3x daily is commonly discussed for pulsatile release. Protocols often run 3-6 months followed by 1-2 month breaks. This is not medical advice.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Health & Longevity | 200mcg | 1x daily before bed | SubQ |
| Body Composition | 250-300mcg | 2x daily (morning, pre-workout) | SubQ |
| Athletic Performance | 200-250mcg | 2-3x daily | SubQ |
| Sleep & Recovery | 200mcg | 1x daily 30min before bed | SubQ |
| Anti-Aging Protocol | 200-250mcg | 1-2x daily | SubQ |
Timing: Injectable Ipamorelin is most effective on an empty stomach. For sleep benefits, inject 30 minutes before bed. For body composition, consider morning fasted injection or pre-workout timing.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean work area and hands thoroughly with antibacterial soap
Gather all materials and let refrigerated peptide reach room temperature
Calculate required BAC water volume using the calculator
Draw calculated BAC water amount into syringe
Inject BAC water slowly down the side of vial (never directly onto powder)
Gently swirl vial until completely dissolved (never shake vigorously)
Store reconstituted solution in refrigerator, use within 28 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White, Fine Crystalline Powder
Quality Ipamorelin appears as white, fine crystalline powder filling the vial bottom.
Clear Solution After Reconstitution
When properly mixed with BAC water, solution should be crystal clear.
Mild Hunger Response
Quality Ipamorelin should produce mild hunger increase 20-30 minutes after injection.
Slight Drowsiness (Bedtime Doses)
When taken before bed, may cause mild drowsiness as GH release promotes natural sleep onset.
Yellow or Discolored Powder
Any discoloration suggests degradation or contamination.
No Physiological Response
Lack of any response after 1-2 weeks may indicate inactive peptide.
What to Expect
- •Week 1-2: Improved sleep quality, deeper sleep, better morning energy
- •Week 2-4: Enhanced recovery from exercise, reduced muscle soreness
- •Week 4-8: Body composition improvements, increased lean mass, fat loss
- •Week 8-12: Continued improvements in muscle tone, skin quality, energy
- •Side effects: Minimal, occasional mild hunger 20-30 minutes post-injection
- •Most effective for: Sleep optimization, body recomposition, anti-aging
Side Effects & Safety
Side Effects
- •Use sterile injection technique to prevent infection
- •May cause mild hunger increase 20-30 minutes post-injection
- •Monitor for receptor desensitization after 3-4 months
- •Cycle off periodically to maintain effectiveness
- •Not recommended during pregnancy, breastfeeding, or active cancer
When to Stop
- •Signs of infection at injection site
- •Allergic reactions
- •Unusual swelling or discomfort
- •If advised by healthcare provider
- •Before any medical procedures
References
5 StudiesPhase II Postoperative Ileus Trials
Human | Double-blind placebo-controlled | NCT01280344 | GI recovery post-surgery
Completed Phase II trials evaluated Ipamorelin's safety and efficacy versus placebo for gastrointestinal recovery after bowel resection, demonstrating good tolerability in surgical populations.
Bone Growth Promotion Study
Rodent model | Various doses | Bone density markers
Preclinical research demonstrated bone growth promotion and muscle preservation against steroid-induced breakdown, with enhanced tetanic tension when combined with CJC-1295.
CJC-1295/Ipamorelin Combination Research
Animal model | Glucocorticoid-damaged muscle | Synergistic effects
Combination therapy with CJC-1295 showed improved tetanic tension and muscle recovery in glucocorticoid-damaged tissue, supporting complementary sustained vs rapid GH pulse mechanisms.
Quick Start Guide
Research Disclaimer
Ipamorelin is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Ipamorelin must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Ipamorelin for any purpose. Consult qualified professionals for any research applications.